

R^2, R^3, R^4 and R^5 are hydrogen,
 R^6 is methyl,
 R^7 is hydrogen, C_{1-6} alkyl, which is optionally substituted with phenyl, $COOC_{1-6}$ alkyl or $CO-C_{1-6}$ alkyl,
 R^8 is hydrogen, C_{1-6} alkyl, which is optionally substituted with phenyl, $COOC_{1-6}$ alkyl or COC_{1-6} alkyl,
A is a straight-chain or branched C_{1-6} alkylene, straight-chain or branched C_{1-6} alkenylene or $-(CH_2)_p-Q-(CH_2)_q-$,
B is hydrogen or $-(CH_2)_p-U$,
Q is C_{3-7} cycloalkyl, indanyl, 5-, 6- or 7-membered saturated heterocycloalkyl with 1-2 N, O or S atoms, C_6-C_{10} aryl or 5- or 6-membered heteroaryl with 1-3 N, O or S atoms, which is optionally annellated with benzene,
U is hydrogen, C_{1-6} alkyl optionally substituted with halogen, C_{3-7} cycloalkyl, indanyl, C_{7-10} bicycloalkyl, C_6-C_{10} aryl or 5- or 6-membered heteroaryl with 1-3 N, O or S atoms, which is optionally annellated with benzene, wherein the aryl or heteroaryl radical is optionally substituted with halogen, C_{1-4} alkyl, C_{1-4} alkoxy, CF_3 , NO_2 , NH_2 , $N(C_{1-4} \text{ alkyl})_2$, cyano, $CONH_2$, $-O-CH_2-O-$, $-O-(CH_2)_2-O-$, SO_2NH_2 , OH , phenoxy or $COOC_{1-4}$ alkyl,
 R^8 and B together with the nitrogen atom optionally form a 5- to 7-membered saturated heterocycle, which optionally contains another oxygen, nitrogen or sulfur atom and is optionally substituted with C_{1-4} alkyl, phenyl, benzyl or benzoyl or form an unsaturated 5-membered heterocycle, which optionally contains 1-3 N atoms and is optionally substituted with phenyl, C_{1-4} alkyl or halogen,
 R^7 and A together with the nitrogen atom optionally form a 5- to 7-membered saturated heterocycle, which optionally contains another oxygen, nitrogen or sulfur atom or forms an unsaturated 5-membered heterocycle, which optionally contains 1-3 N atoms,
m is 0, 1 or 2,
n and r is 0, 1 to 6,
p and q is 0 to 6,

Sub B1
A1
R⁹ and R¹⁰ is hydrogen or C₁₋₆ alkyl,

R¹¹ is C₁₋₆ alkyl, -NH₂, -NH-CH₃, -NH-CN, C₆₋₁₀ aryl optionally substituted with halogen, C₁₋₄ alkyl or CF₃, or 5- or 6-membered heteroaryl with 1 to 4 nitrogen, sulfur or oxygen atoms that is optionally substituted with halogen, C₁₋₄ alkyl or CF₃,

R¹² and R¹³ are hydrogen, C₁₋₆ alkyl, phenyl optionally substituted with halogen or C₁₋₄ alkyl, benzyl optionally substituted with halogen or C₁₋₄ alkyl, or C₃₋₇ cycloalkyl,

R¹⁴ is hydrogen, hydroxy, C₁₋₆ alkoxy, phenyl, C₁₋₆ alkyl optionally substituted with CO₂H, CO₂C₁₋₆ alkyl, hydroxy, C₁₋₄ alkoxy, halogen, NR¹⁵R¹⁶, CONR¹²R¹³, phenyl, or C₂₋₆ alkenyl optionally substituted with phenyl, cyano, CONR¹²R¹³ or CO₂C₁₋₄ alkyl,

R¹⁵ and R¹⁶ are hydrogen, C₁₋₆ alkyl, phenyl or benzyl, and

R¹⁵ and R¹⁶ together with the nitrogen atom optionally form a saturated 5-, 6-, or 7-membered ring, which optionally contains another nitrogen, oxygen or sulfur atom and is optionally substituted with C₁₋₄ alkyl, phenyl, benzyl or benzoyl,

wherein

R¹ is not 6-((4-aminobenzyl)aminomethyl), 6-((4-dimethylaminobenzyl)aminomethyl), 6-((4-aminobenzyl) (tert-butyloxycarbonyl)aminomethyl), or 6-((4-dimethylaminobenzyl) (tert-butyloxycarbonyl)aminomethyl).

Please cancel claims 2-5 without prejudice or disclaimer.

A2 Sub B2
6. (Twice Amended) A compound according to claim 1, wherein R¹ and R² together with two adjacent carbon atoms form a 3- to 8-membered ring, that is substituted with -(CHR⁹)_r-NR⁷-A-NR⁸B.

A3 Sub B1
7. (Amended) A compound according to claim 6, wherein r = 0.

A4 Sub B1
8. (Twice Amended) A compound according to claim 1, wherein A is a straight-

A4

chain or branched C₁₋₆ alkylene or -(CH₂)_p-Q-(CH₂)_q-, wherein p and q are each independently 1-

4.

9. (Amended) A compound according to claim 1, wherein U is hydrogen, alkyl that is optionally substituted with halogen, C₃₋₇ cycloalkyl or optionally substituted phenyl.

10. (Amended) A compound according to claim 1, which is
6-((3-aminomethyl)-benzyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-(meta-(N-[3-keto-2-methyl-2H-1,4-benzoxazin-6-yl]-methyl-aminomethyl)-benzyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-(meta-(N-[3-amino-2-methyl-2H-1,4-benzoxazin-6-yl]-methyl-aminomethyl)-benzyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-((4-aminomethyl)-benzyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-(para-(N-[3-amino-2-methyl-2H-1,4-benzoxazin-6-yl]-methyl-aminomethyl)-benzyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-(para-(N-[3-keto-2-methyl-2H-1,4-benzoxazin-6-yl]-methyl-aminomethyl)-benzyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-((3-aminomethyl-cyclohex-1-yl)-methyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-(3-(N-[3-amino-2-methyl-2H-1,4-benzoxazin-6-yl]-methyl-aminomethyl)-cyclohex-1-ylmethyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-((omega-aminobutyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-((omega-aminopentyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-((omega-aminohexyl-aminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-((3-[4-nitrobenzyl]-aminomethyl)-benzylaminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

Sub D1 AS
6-((3-[2-methylbenzyl]-aminomethyl)-benzylaminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-((3-[2,4-dichlorobenzyl]-aminomethyl)-benzylaminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-((3-[chlorobenzyl]-aminomethyl)-benzylaminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride,

6-((3-[3,4-dichlorobenzyl]-aminomethyl)-benzylaminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride, or


6-((3-benzylaminomethyl)-benzylaminomethyl)-3-amino-2-methyl-2H-1,4-benzoxazine trihydrochloride.

Sub D1 AS
11. (Twice Amended) A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically-acceptable auxiliaries.


12. (Twice Amended) A method of treating a disease that is triggered by NOS comprising administering to a patient in need thereof a pharmaceutical composition according to claim 11.

Sub D1 AS
13. (Amended) A method of treating a neurodegenerative disease comprising administering to a patient in need thereof a pharmaceutical composition according to claim 11.

AS
Sub D1
14. (Twice Amended) A process for preparing a compound of claim 1, comprising reacting a compound of formula IIa or IIb or a salt thereof



IIa




IIb


wherein

R^1 , R^2 , R^3 , R^5 , R^6 and X are as defined in claim 1, Z is oxygen or sulfur and R is a C_{1-6} alkyl, with ammonia or a primary amine.

15. (Amended) A compound of formula IIa or IIb



IIa



IIb

wherein

R^1 is $-(CHR^9)_n-NR^7-A-NR^8-B$,

R^2 , R^3 , R^4 and R^5 are hydrogen,

R^6 is methyl,

X is oxygen or sulfur, and R is a C_{1-6} alkyl.